VPV. E. Popova

V. E. Popova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


V. E. Popova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Systemic drug therapy for metastatic uterine leiomyosarcoma: treatment results from real clinical practice

    by S. L. Gutorov, Гуторов С. Л., A. Y. Anokhin, Анохин А. Ю., T. E. Tikhomirova, Тихомирова Т. Е., Y. M. Mesropova, Месропова Ю. М., A. K. Zarenkova, Заренкова А. К., et al.

    Background. Currently, adjuvant chemotherapy of choice after surgical treatment of uterine leiomyosarcoma is doxorubicin. The same approach is used for the 1st line of systemic drug therapy in patients with initially metastatic process, or those who have not previously received adjuvant treatment with anthracyclines. Disseminated forms of metastatic leiomyosarcoma are characterized by unfavorable prognosis, and the options for potentially effective drug treatments are limited. Aim. To evaluate the efficacy of 1st and 2nd line chemotherapy regimens for uterine leiomyosarcoma in a population of patients in real clinical practice. Materials and methods. The retrospective analysis included 43 patients with histologically verified uterine leiomyosarcoma. The study included patients with primarily localized forms of the disease, who underwent surgical treatment at the 1st stage (with or without adjuvant chemotherapy), and patients with initially metastatic disease. All patients had a history of 1–2 lines of systemic drug therapy due to disease progression. Results. The analysis included 43 patients who underwent treatment at the N. N. Blokhin National Medical Research Center of Oncology between 2021 and 2024. The efficacy of the 1st line was assessed in 35 (81.4 %) patients: the objective response rate reached 17.6 %, and median progression-free survival from the start of the 1st line was 7.4 months. The efficacy of 2nd line of therapy was assessed in 18 (41.9 %) patients: the objective response rate was 11.1 %, median progression-free survival from the start of the 1st line to progression after the 2nd line was 13.2 months, and median progression-free survival from the start of the 2nd line to progression after it was 3.3 months. Conclusion. Analysis of the efficacy of systemic drug therapy for uterine leiomyosarcoma in real clinical practice demonstrates comparable long-term treatment results with data from international literature. Further study of the efficacy of combined adjuvant and 1st line therapy regimens seems promising.

  • Open Access

    Surgical treatment of patients with pelvic bone metastases

    by D. I. Sofronov, E. A. Sushentsov, D. K. Agaev, K. A. Borzov, Ya. A. Dzhamukhanova, V. E. Popova, M. D. Adzhieva, V. B. Fedorova, V. B. Matveev, A. K. Valiev, et al.

    Introduction. Pelvic bone metastases are a common complication of malignant tumors, leading to pain, pathological fractures, and decreased quality of life. Surgical treatment plays a key role in palliative care, but the optimal approaches remain controversial.Aim. To evaluate the results of surgical treatment of patients with pelvic bone metastases, including oncologic and functional outcomes, as well as complication rates.Materials and methods. A retrospective analysis of 39 patients (21 men, 18 women; median age 55 years) who underwent surgical treatment for metastatic pelvic bone lesions in the period 2002–2022 was performed. The most common localizations were the ilium (10 (25.6 %) cases) and sacrum (13 (33.3 %) cases). A solitary lesion was detected in 33 (84.6 %) patients and multiple bone lesions in 6 (5.4 %) patients. The primary lesion in most cases (in 19 (48.7 %) patients) was kidney cancer. Radical (wide resections) (71.8 % cases) and palliative (decompression and excohleations) (23.1 % cases) methods were used. Survival, complications (according to the Clavien–Dindo classification), pain dynamics (according to the visual analog and Watkins scales) and functional status (according to the Karnofsky scale) were assessed.Results. Complications developed in 28.2 % of patients, mainly after resections involving the acetabulum (p = 0.029). The leading complications were deep infections (8 cases), superficial necrosis (3 cases), which required additional surgical interventions. The median overall survival was 45 months, with solitary metastases – 93 months, with multiple metastases – 20 months (p = 0.019). Intralesional resections were associated with worse survival (p = 0.028). A significant decrease in pain (from 5 to 2 according to the visual analog scale; p 0.001) and improvement in functional status (according to the Karnofsky scale; p = 0.022) were noted. Conclusion. Radical resections provide better survival in solitary metastases group, while palliative methods are appropriate for multiple lesions. The choice of tactics requires a multidisciplinary approach, taking into account the prognosis and extent of the lesion.